喘息薬の世界市場レポート 2025年

喘息薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.2％で319億8,000万米ドルに成長します。予測期間の成長は、大気汚染レベルの上昇、高齢化人口の増加、ヘルスケア意識の高まり、個別化医療の動向、バイオ医薬品の革新に起因すると考えられます。予測期間の主な動向には、低分子治療、在宅喘息ケア、バイオマーカー誘導治療、重症喘息治療の進歩、喘息研究のための共同研究などがあります。

喘息の有病率の上昇は、喘息薬市場の成長を促進すると予想されます。喘息は、気道の炎症と腫脹を特徴とする慢性疾患で、気道の狭窄を引き起こし、鼻や口から肺への空気の流れを制限します。喘息患者の増加により、喘息性疾患に対処するための新薬の開発が著しく増加しています。例えば、2024年4月、英国を拠点に肺疾患患者を支援する慈善団体Asthma+Lung UKは、英国における喘息関連死が2021年の1,146人から2022年には1,236人に増加したと報告しました。この増加は、過去1年間における喘息に関連した死亡者数の厄介な増加傾向を浮き彫りにしています。

呼吸器疾患の有病率の増加は、喘息薬市場を強化することになります。呼吸器疾患は、肺、気管支、気管、喉頭、咽頭、鼻腔などの呼吸器系に影響を及ぼす病状です。呼吸器疾患の増加は、これらの疾患に関連する症状を管理・緩和するための喘息薬に対する需要を煽る。呼吸器疾患、特に慢性の炎症や気道狭窄を伴う喘息のような疾患が一般的になるにつれ、効果的な治療ソリューションの必要性が高まっています。例えば、2024年9月、米国に本部を置く専門組織である米国肺協会は、2023年には米国で3,500万人以上が喘息やCOPDなどの慢性肺疾患とともに生活していると報告しました。人口の4.6％にあたる約1,170万人の成人が、慢性気管支炎や肺気腫を含むCOPDと診断されています。その結果、呼吸器疾患の有病率の上昇が喘息薬市場を前進させると思われます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の喘息薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の喘息薬市場：成長率分析
• 世界の喘息薬市場の実績：規模と成長, 2019-2024
• 世界の喘息薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の喘息薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の喘息薬市場：喘息タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アレルギー
• 非アレルギー
• 世界の喘息薬市場：喘息誘因タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人発症喘息
• 小児喘息
• 咳喘息
• 運動誘発性喘息
• 職業性喘息
• 夜間喘息
• ステロイド抵抗性喘息
• 世界の喘息薬市場：療法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予防
• 治癒
• 世界の喘息薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 気管支拡張薬
• モノクローナル抗体
• 抗炎症薬
• 併用薬
• 世界の喘息薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喘息患者
• COPD患者
• 世界の喘息薬市場、タイプ別サブセグメンテーション：アレルギー、実績と予測, 2019-2024, 2024-2029F, 2034F
• 吸入コルチコステロイド（ICS）
• ロイコトリエン受容体拮抗薬（LTRA）
• モノクローナル抗体
• 世界の喘息薬市場、タイプ別サブセグメンテーション：非アレルギー、実績と予測, 2019-2024, 2024-2029F, 2034F
• 短時間作用型ベータ刺激薬（SABA）
• 長時間作用型ベータ刺激薬（LABA）
• 経口コルチコステロイド

第7章 地域別・国別分析

• 世界の喘息薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の喘息薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 喘息薬市場：競合情勢
• 喘息薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC.
• GlaxoSmithKline PLC.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Novartis International AG
• Mylan N.V.
• Cipla Limited
• Chiesi Farmaceutici S.p.A.
• Sun Pharmaceutical Industries Limited
• Hikma Pharmaceuticals
• Mundipharma International Limited
• Lupin Limited
• Glenmark Pharmaceuticals Limited
• Hetero Drugs Limited
• Alembic Pharmaceuticals Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 喘息薬市場2029：新たな機会を提供する国
• 喘息薬市場2029：新たな機会を提供するセグメント
• 喘息薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Asthma is a chronic respiratory condition characterized by inflammation and constriction of the airways, resulting in difficulty breathing. This condition is triggered by factors such as allergens, leading to airway narrowing and excess mucus production. Asthma drugs play a vital role in managing symptoms associated with asthma.

Asthma can be categorized into allergic and non-allergic types. Allergic asthma involves airway constriction triggered by exposure to allergens, leading to respiratory difficulties. Various triggers for asthma include adult-onset asthma, child-onset asthma, cough-induced asthma, exercise-induced asthma, occupational asthma, nocturnal asthma, and steroid-resistant asthma. Asthma drugs are classified into bronchodilators, monoclonal antibodies, anti-inflammatory drugs, and combination drugs, catering to the needs of asthma and COPD patients.

The asthma drugs market research report is one of a series of new reports from The Business Research Company that provides asthma drugs market statistics, including the asthma drugs industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed asthma drugs market segments, asthma drugs market trends, and opportunities, and any further data you may need to thrive in the asthma drugs industry. This asthma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The asthma drugs market size has grown strongly in recent years. It will grow from $23.96 billion in 2024 to $25.17 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to environmental factors, increased respiratory disorders, lifestyle changes, healthcare infrastructure development

The asthma drugs market size is expected to see strong growth in the next few years. It will grow to $31.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to rising air pollution levels, growing aging population, increasing healthcare awareness, personalized medicine trends, biopharmaceutical innovations. Major trends in the forecast period include small molecule therapies, home-based asthma care, biomarker-guided therapies, therapeutic advances in severe asthma, collaborations for asthma research.

The rising prevalence of asthma is anticipated to drive growth in the asthma drug market. Asthma is a chronic condition characterized by inflammation and swelling of the airways, which leads to their narrowing and restricts airflow from the nose and mouth to the lungs. Due to the increasing number of asthma cases, there has been a significant rise in the development of new medications to address asthmatic disorders. For example, in April 2024, Asthma + Lung UK, a charity based in England that assists individuals with lung conditions, reported that asthma-related deaths in England rose from 1,146 in 2021 to 1,236 in 2022. This increase highlights a troubling upward trend in fatalities linked to the condition over the past year.

The increasing prevalence of respiratory diseases is set to enhance the asthma drug market. Respiratory diseases are medical conditions that impact the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. The rise in respiratory diseases fuels the demand for asthma medications to manage and relieve symptoms associated with these conditions. As respiratory diseases become more common, particularly those like asthma that involve chronic inflammation and airway constriction, the need for effective therapeutic solutions grows. For example, in September 2024, the American Lung Association, a professional organization based in the U.S., reported that over 35 million people in the U.S. were living with a chronic lung condition, such as asthma or COPD, in 2023. Approximately 11.7 million adults, or 4.6% of the population, have been diagnosed with COPD, which encompasses chronic bronchitis and emphysema. Consequently, the rising prevalence of respiratory diseases will propel the asthma drug market forward.

Innovative product development stands as a significant trend gaining traction within the asthma drug market. Major players within this sector are strategically focused on creating novel solutions to maintain their market position. An illustration of this trend is evident in the collaboration between Amgen, a US-based biopharmaceutical company, and AstraZeneca, a UK-based biopharmaceutical company, resulting in the FDA approval of Tezpire, an injectable drug engineered to alleviate asthma symptoms. Tezpire's mechanism of action involves curbing inflammation linked to asthma attacks, exhibiting potential benefits for individuals with severe asthma, including those previously lacking effective treatment options. As the first biologic to consistently reduce asthma-related exacerbations in Phase 2 and 3 clinical trials, the approval of Tezpire promises greater therapeutic advantages, aligning with the escalating instances of asthma cases.

Major companies in the asthma drugs market are prioritizing innovations like fixed-dose combination (FDC) drugs to improve treatment effectiveness and patient adherence. An FDC drug is a medication that combines two or more active ingredients into a single dosage form, such as a tablet, capsule, or inhaler. For example, in June 2022, Glenmark Pharmaceuticals, a pharmaceutical company based in India, launched Indamet, a fixed-dose combination drug aimed at patients with uncontrolled asthma. This innovative treatment merges Indacaterol, a long-acting beta-agonist, with Mometasone Furoate, an inhaled corticosteroid, and is available in various strengths, including Indacaterol 150 mcg with Mometasone at 80 mcg, 160 mcg, and 320 mcg. Designed for once-daily use, Indamet is intended for adults and adolescents aged 12 years and older.

In March 2022, Sandoz, a German pharmaceutical company, successfully acquired Coalesce Product Development Limited for an undisclosed sum. This strategic acquisition aligns with Sandoz's goal of expanding its respiratory division's portfolio and solidifying its global leadership in respiratory products. Through this transaction, Sandoz gains valuable assets and enhanced capabilities in medical and drug-device development, particularly in the respiratory and complex generics markets. The acquisition positions Sandoz to better serve patients with respiratory diseases, including asthma and COPD, by offering affordable and high-quality drug-device combination products, such as inhalers. Coalesce Product Development Limited, based in the UK, is a company specializing in the development of drug delivery devices, boasting a diverse portfolio that includes pressurized metered-dose inhalers, breath-actuated inhalers, pre-metered dry powder inhalers, and more.

Major companies operating in the asthma drugs market include Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd, Innoviva Inc., Vectura Group, Circassia Group PLC, Pulmatrix Inc., Atopix Therapeutics Limited

North America was the largest region in the asthma drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the asthma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma drugs market consists of sales of drugs such as bronchodilators (beta-2 agonists), monoclonal antibodies (omalizumab, mepolizumab), and anti-inflammatory drugs (budesonide, ciclesonide), used for the treatment of asthma in patients of all ages. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asthma Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on asthma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for asthma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The asthma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Asthma: Allergic; Non-Allergic
• 2) By Asthma Trigger Type: Adult-Onset Asthma; Child-Onset Asthma; Cough-Induced Asthma; Exercise-Induced Asthma; Occupational Asthma; Nocturnal Asthma; Steroid-Resistant Asthma
• 3) By Therapy: Preventive; Curative
• 4) By Drug Class: Bronchodilators; Monoclonal Antibodies; Anti-Inflammatory Drugs; Combination Drugs
• 5) By End-User: Asthma Patients; COPD Patients
• Subsegments:
• 1) By Allergic: Inhaled Corticosteroids (ICS); Leukotriene Receptor Antagonists (LTRAs); Monoclonal Antibodies
• 2) By Non-Allergic: Short-Acting Beta Agonists (SABAs); Long-Acting Beta Agonists (LABAs); Oral Corticosteroids
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Asthma Drugs Market Characteristics

3. Asthma Drugs Market Trends And Strategies

4. Asthma Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Asthma Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Asthma Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Asthma Drugs Market Growth Rate Analysis
• 5.4. Global Asthma Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Asthma Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Asthma Drugs Total Addressable Market (TAM)

6. Asthma Drugs Market Segmentation

• 6.1. Global Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Allergic
• Non-Allergic
• 6.2. Global Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult-Onset Asthma
• Child-Onset Asthma
• Cough-Induced Asthma
• Exercise-Induced Asthma
• Occupational Asthma
• Nocturnal Asthma
• Steroid-Resistant Asthma
• 6.3. Global Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive
• Curative
• 6.4. Global Asthma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bronchodilators
• Monoclonal Antibodies
• Anti-Inflammatory Drugs
• Combination Drugs
• 6.5. Global Asthma Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma Patients
• COPD Patients
• 6.6. Global Asthma Drugs Market, Sub-Segmentation Of Allergic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhaled Corticosteroids (ICS)
• Leukotriene Receptor Antagonists (LTRAs)
• Monoclonal Antibodies
• 6.7. Global Asthma Drugs Market, Sub-Segmentation Of Non-Allergic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-Acting Beta Agonists (SABAs)
• Long-Acting Beta Agonists (LABAs)
• Oral Corticosteroids

7. Asthma Drugs Market Regional And Country Analysis

• 7.1. Global Asthma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Asthma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Asthma Drugs Market

• 8.1. Asia-Pacific Asthma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Asthma Drugs Market

• 9.1. China Asthma Drugs Market Overview
• 9.2. China Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Asthma Drugs Market

• 10.1. India Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Asthma Drugs Market

• 11.1. Japan Asthma Drugs Market Overview
• 11.2. Japan Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Asthma Drugs Market

• 12.1. Australia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Asthma Drugs Market

• 13.1. Indonesia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Asthma Drugs Market

• 14.1. South Korea Asthma Drugs Market Overview
• 14.2. South Korea Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Asthma Drugs Market

• 15.1. Western Europe Asthma Drugs Market Overview
• 15.2. Western Europe Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Asthma Drugs Market

• 16.1. UK Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Asthma Drugs Market

• 17.1. Germany Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Asthma Drugs Market

• 18.1. France Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Asthma Drugs Market

• 19.1. Italy Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Asthma Drugs Market

• 20.1. Spain Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Asthma Drugs Market

• 21.1. Eastern Europe Asthma Drugs Market Overview
• 21.2. Eastern Europe Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Asthma Drugs Market

• 22.1. Russia Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Asthma Drugs Market

• 23.1. North America Asthma Drugs Market Overview
• 23.2. North America Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Asthma Drugs Market

• 24.1. USA Asthma Drugs Market Overview
• 24.2. USA Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Asthma Drugs Market

• 25.1. Canada Asthma Drugs Market Overview
• 25.2. Canada Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Asthma Drugs Market

• 26.1. South America Asthma Drugs Market Overview
• 26.2. South America Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Asthma Drugs Market

• 27.1. Brazil Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Asthma Drugs Market

• 28.1. Middle East Asthma Drugs Market Overview
• 28.2. Middle East Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Asthma Drugs Market

• 29.1. Africa Asthma Drugs Market Overview
• 29.2. Africa Asthma Drugs Market, Segmentation By Type Of Asthma, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Asthma Drugs Market, Segmentation By Asthma Trigger Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Asthma Drugs Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Asthma Drugs Market Competitive Landscape And Company Profiles

• 30.1. Asthma Drugs Market Competitive Landscape
• 30.2. Asthma Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Asthma Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC.
• 31.2. GlaxoSmithKline PLC.
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Novartis International AG
• 31.6. Mylan N.V.
• 31.7. Cipla Limited
• 31.8. Chiesi Farmaceutici S.p.A.
• 31.9. Sun Pharmaceutical Industries Limited
• 31.10. Hikma Pharmaceuticals
• 31.11. Mundipharma International Limited
• 31.12. Lupin Limited
• 31.13. Glenmark Pharmaceuticals Limited
• 31.14. Hetero Drugs Limited
• 31.15. Alembic Pharmaceuticals Limited

32. Global Asthma Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Asthma Drugs Market

34. Recent Developments In The Asthma Drugs Market

35. Asthma Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Asthma Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Asthma Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Asthma Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer